Lilly Takes Aim At Synthon Over Adcirca ANDA

Law360, New York (March 18, 2010, 4:36 PM EDT) -- Eli Lilly & Co. has filed a patent infringement suit against Synthon Pharmaceuticals Inc. over its attempt to introduce a generic version of hypertension drug Adcirca.

Indianapolis-based Lilly filed suit Monday in the U.S. District Court for the Southern District of Indiana, in response to Synthon's efforts to gain U.S. Food and Drug Administration approval for its product.

Synthon told Lilly in a Jan. 28 letter that its abbreviated new drug application contained a Paragraph IV certification claiming the product would not infringe the patents for...
To view the full article, register now.